Moderators: XenaLives , runncoach , Cyosol , Battle Ready , urge2surge
Search This Board: 
Created: 10/11/2013 03:39:59 PM - Followers: 113 - Board type: Free - Posts Today: 0

 

Description:
Synaptogenix (formerly known as Neurotrope) is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. For more information, visit: https://www.synaptogen.com/

Market Information (as of April 14, 2022):
Symbol: SNPX
Stock Price: $7.03
Market Cap: $47,871,818
Outstanding Shares: 6,809,647
Outstanding Warrants & Options:

Pre-funded Warrants:
- 83,334 Pre-funded Warrants to purchase 83,334 shares of Common Stock, with an exercise price of $0.04 per share ($3,333)
- 66,251 Pre-funded Warrants to purchase 66,251 shares of Common Stock, with an exercise price of $0.01 per share ($663)

January 2021 Offering Warrants (expires April 29, 2022):
- 1,049,368 Series E Warrants to purchase 1,049,368 shares of Common Stock, with an exercise price of $8.51 per share ($8,930,122)

December 2020 Spin-off Warrants (expires December 7, 2025):
- 39,535 Series A Warrants to purchase up to 39,535 shares of Common Stock with an exercise price of $198.80 per share ($7,859,558)
- 155,917 Series B Warrants to purchase up to 155,917 shares of Common Stock with an exercise price of $79.52 per share ($12,398,520)
- 227,163 Series C Warrants to purchase up to 227,163 shares of Common Stock with an exercise price of $39.76 per share ($9,032,001)
- 555,462 Series D Warrants to purchase up to 555,462 shares of Common Stock with an exercise price of $15.92 per share ($8,842,955)

January 2021 Offering Warrants (expires January 25, 2026):
- 2,029,179 Series F Warrants to purchase up to 2,029,179 shares of Common Stock with an exercise price of $6.90 per share ($14,001,335)
 
January 2021 Offering Warrants (expires January 29, 2026):
- 206,057 Placement Agent Warrants to purchase up to 206,057 shares of Common Stock with an exercise price of $6.90 per share ($1,421,793)

Consulting Warrants (expires February 16, 2026):
- 35,000 Consulting Warrants to purchase up to 35,000 shares of Common Stock with an exercise price of $11.46 per share ($401,100)
 
Consulting Warrants (expires April 1, 2026):
- 7,000 Consulting Warrants to purchase up to 7,000 shares of Common Stock with an exercise price of $8.80 per share ($61,600)

June 2021 Offering Warrants (expires June 16, 2026):
- 1,573,281 Series G Warrants to purchase up to 1,573,281 shares of Common Stock with an exercise price of $8.51 per share ($13,388,621)
- 152,378 Placement Agent Warrants to purchase up to 152,378 shares of Common Stock with an exercise price of $8.51 per share ($1,296,737)

Consulting Warrants (expires July 1, 2026):
- 10,300 Consulting Warrants to purchase up to 10,300 shares of Common Stock with an exercise price of $9.76 per share ($100,528)

Consulting Warrants (expires October 1, 2026):
- 10,300 Consulting Warrants to purchase up to 10,300 shares of Common Stock with an exercise price of $9.30 per share ($95,790)

Consulting Warrants (expires January 3, 2027):
- 10,300 Consulting Warrants to purchase up to 10,300 shares of Common Stock with an exercise price of $8.69 per share ($89,507)
 
Options:
- 123,850 Options to purchase up to 123,850 shares of Common Stock with a weighted-average exercise price of $9.84 per share ($1,218,684)
 
To be raised from exercised warrants & options: $79,142,847
Fully diluted shares (Outstanding Shares + Warrants + Options): 13,144,322
Fully diluted market cap: $92,404,584


Press Releases:
Phase 2a results (2015): https://www.prnewswire.com/news-releases/neurotrope-announces-positive-top-line-results-from-its-phase-2a-study-of-bryostatin-1-in-alzheimers-disease-300038367.html

Exploratory Phase 2b results (2017): https://www.prnewswire.com/news-releases/neurotrope-announces-positive-top-line-results-from-phase-2-study-of-bryostatin-1-for-moderate-to-severe-alzheimers-disease-300448563.html
Exploratory Phase 2b analysis (2018): https://www.prnewswire.com/news-releases/neurotropes-bryostatin-improves-cognition-in-patients-with-advanced-alzheimers-disease-based-on-further-analysis-of-phase-2-clinical-trial-data-300578025.html

Confirmatory Phase 2b results (2019): https://www.prnewswire.com/news-releases/neurotrope-announces-top-line-results-from-confirmatory-phase-2-study-of-bryostatin-1-in-moderate-to-severe-alzheimers-disease-300913655.html
Confirmatory Phase 2b analysis (2020): https://www.prnewswire.com/news-releases/neurotrope-provides-corporate-update-after-completing-bryostatin-1-data-analysis-for-advanced-alzheimers-disease-trial-300991105.html

Scientific Articles:
[P2a & CU results] "Bryostatin Effects on Cognitive Function and PKC epsilon in Alzheimer’s Disease Phase IIa and Expanded Access Trials" (2017): https://pdfhost.io/v/XAcILs@Hc_jad2F20172F5822Fjad582jad1701612Fjad58jad170161pdf.pdf
[Exploratory P2b results] "A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Ef?cacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease" (2018): https://pdfhost.io/v/GEa58CPiF_farlow2018pdf.pdf
[Memantine results] "Memantine in Moderate-to-Severe Alzheimer's Disease" (2003): https://www.nejm.org/doi/full/10.1056/NEJMoa013128
More scientific articles: https://pdfhost.io/v/.~Rt1cU63_bryo1.pdf


Media:
"A new era for treating diseases of the brain" (2008): https://youtu.be/W1pdg1kvQHI
"Rockefeller Institute drug provides hope for Alzheimer’s treatment" (2015): https://www.wvgazettemail.com/news/rockefeller-institute-drug-provides-hope-for-alzheimer-s-treatment/article_bf5bab5f-e40e-5f47-95ca-666f14b795e0.html
"The Scoop: Alzheimer’s Drug Tries to Build Up a Head of Steam" (2018): https://www.genengnews.com/magazine/the-scoop-alzheimers-drug-tries-to-build-up-a-head-of-steam/
"Advancements in Alzheimer’s Treatment: Interview with Dr. Daniel Alkon" (2018): https://newyork.legalexaminer.com/health/senior-care/advancements-in-alzheimers-treatment-interview-with-dr-daniel-alkon/
"Company Seeks to Prove Marine-Derived Alzheimer's Drug Is No Fish Story" (2019): https://soundcloud.com/levine-media-group/company-seeks-to-prove-marine-derived-alzheimers-drug-is-no-fish-story
"Pizza Hut co-founder’s compassionate-care Alzheimer’s trial leads to hope for others" (2019): https://www.kansas.com/news/business/biz-columns-blogs/carrie-rengers/article229253744.html
"After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug" (2019): https://www.npr.org/sections/health-shots/2019/05/03/718754791/after-a-big-failure-scientists-and-patients-hunt-for-a-new-type-of-alzheimers-d
Dr. Alkon at Alzheimer's Solutions Conference (2019): https://www.youtube.com/watch?v=bP5GcAplXls
How an Alzheimer’s ‘cabal’ thwarted progress toward a cure (2019): https://www.statnews.com/2019/06/25/alzheimers-cabal-thwarted-progress-toward-cure/
Charles Ryan On Treating Alzheimer's Disease (2019): https://tdameritradenetwork.com/video/rB4AoWt8Hk2Ba5865CUHvQ
The Impacts of Alzheimer's Disease are Growing (2019): https://www.youtube.com/watch?v=x4NkJqASGZc
Synaptogenix | Investor Presentation | Benzinga Global Small Cap Conference (2021): https://youtu.be/XW6p2kImbvM
Company Overview: Synaptogenix (SNPX) - Possible New Alzheimer's Treatment (2021): https://tdameritradenetwork.com/video/rB4A-HpDFiiBekSTg3kAXQ
Synaptogenix | Benzinga Healthcare Small Cap Conference (2021): https://www.youtube.com/watch?v=O_UifVfRgfM

Links:
Investor relations: https://www.synaptogen.com/ir/
SEC filings:
Alzheimer's disease drug development pipeline 2021: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145448/
Bryostatin vs. Memantine vs. Placebo comparison: https://i.imgur.com/579PX0L.jpg
Test comparison: https://i.imgur.com/s61opUd.jpg
BryoLogyx: https://bryologyx.com/
NeuroDiagnostics: https://www.ndx-discern.com/
Ongoing trial: https://clinicaltrials.gov/ct2/show/NCT04538066
Institutional Ownership: https://fintel.io/so/us/snpx
Short Interest Data: https://www.shortablestocks.com/?SNPX
Stocktwits: https://stocktwits.com/symbol/SNPX

PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#17218
Quick summary for those that are new: Cyosol 05/25/2021 06:44:41 PM
#16239
Neurotrope is a front for old money and XenaLives 08/29/2020 10:05:05 AM
#16205
FDA trial results. Includes Statistical plan and trial runncoach 07/09/2020 12:25:53 AM
#19657
Looking more and more like a tired hunting urge2surge 07/06/2022 09:52:36 PM
#19656
FDA decision on Eisai, Biogen Alzheimer's drug due novicetrader 07/05/2022 10:14:42 PM
#19655
A little difficult to know to the extent runncoach 07/05/2022 07:19:21 PM
#19654
In this study, was there a difference in Theburg 07/05/2022 07:10:27 PM
#19653
More interesting, current and independent validation. runncoach 07/05/2022 04:19:26 PM
#19652
The full article would be interesting based on runncoach 07/05/2022 04:17:07 PM
#19651
oh, thanks for the feedback, red. Isn't the novicetrader 07/05/2022 01:41:44 PM
#19650
my wife has had it twice. Now redspinelpinktopaz 07/05/2022 11:27:50 AM
#19649
In my opinion the fed tightening and sec urge2surge 07/04/2022 02:37:56 PM
#19648
The market has been undergoing serious manipulation XenaLives 07/04/2022 12:12:12 PM
#19647
I do know people who have gotten shingles runncoach 07/03/2022 03:55:48 PM
#19646
On a related tangent, do you think taking novicetrader 07/03/2022 03:40:45 PM
#19645
Of course none of us really know but runncoach 07/03/2022 02:47:59 PM
#19644
runn, do you have any opinion on the novicetrader 07/03/2022 02:15:46 PM
#19643
Thanks again runncoach. Eom urge2surge 07/03/2022 01:21:46 PM
#19642
Not sure of its status. Signing an runncoach 07/03/2022 12:37:38 PM
#19641
Whatever happened to the initiated trial announced in urge2surge 07/03/2022 12:22:57 PM
#19640
We could always get more but its not runncoach 07/03/2022 07:59:58 AM
#19639
Maybe a general update to shareholder? They went urge2surge 07/02/2022 11:06:35 PM
#19638
Just seems like the level of transparency isn't urge2surge 07/02/2022 11:03:05 PM
#19637
The way I see it most companies with novicetrader 07/02/2022 09:22:38 PM
#19636
No doubt they aren't stock promoters like some runncoach 07/02/2022 08:30:21 PM
#19635
I'm curious to know if anyone has witnessed urge2surge 07/02/2022 08:00:42 PM
#19634
All true but at its current market the runncoach 06/30/2022 08:24:08 PM
#19633
Only issue is. peeved 06/30/2022 08:15:02 PM
#19632
It is. I've mentioned it a few runncoach 06/30/2022 03:13:22 PM
#19631
Anyone in nrsn? Promising data peeved 06/30/2022 12:51:32 PM
#19630
Just a thought but if there's visual evidence urge2surge 06/28/2022 12:02:34 PM
#19629
Not sure what the price might could get runncoach 06/27/2022 08:52:45 PM
#19628
I know you aren’t too keen on avxl peeved 06/27/2022 08:19:45 PM
#19627
It's a tough wait and and a lot runncoach 06/27/2022 08:57:23 AM
#19626
Yes sounds like a big advance. Should help runncoach 06/26/2022 06:06:56 PM
#19625
Runn, have you seen this new method of HANUMAN 06/26/2022 05:23:00 PM
#19624
Not sure to be honest how many were runncoach 06/24/2022 08:37:33 AM
#19623
yeah,also I think this was not publicized much novicetrader 06/24/2022 08:26:56 AM
#19622
I just happened to see it. Didn't realize runncoach 06/24/2022 08:20:52 AM
#19621
runn,curious about one thing.If this was news from novicetrader 06/24/2022 08:15:38 AM
#19620
Biogen AD debacle over. They aren't even runncoach 06/24/2022 08:09:03 AM
#19619
Odd. I mean its only 1500 shares runncoach 06/23/2022 07:21:25 PM
#19618
Looks like the options granted to directors a Cyosol 06/23/2022 06:17:40 PM
#19617
Agreed. Every day that passes without them diluting Cyosol 06/23/2022 06:10:50 PM
#19616
Anybody that can get through Harrison Lab, isn't redspinelpinktopaz 06/23/2022 01:13:24 PM
#19615
No they were not. runncoach 06/23/2022 09:34:48 AM
#19614
Were any of the previous trials sponsored? Would urge2surge 06/23/2022 09:29:55 AM
#19613
You never know but I wouldn't bank on runncoach 06/23/2022 09:24:18 AM
#19612
Great insights. Let's hope that some level of urge2surge 06/23/2022 09:11:25 AM
#19611
AVXL has plenty of cash. They undergo runncoach 06/23/2022 09:01:15 AM
#19610
Agreed on analysts price targets but they are urge2surge 06/23/2022 08:31:25 AM
#19609
Can you imagine? I'll be happy with runncoach 06/23/2022 08:14:27 AM
#19608
$AVXL $40 price target upgrade which gets them urge2surge 06/23/2022 08:10:16 AM
Post Subject